{"entity":{"type":"insider","cik":"0001943192","url":"/insider/0001943192","json_url":"/insider/0001943192.json","name":"Cline Christopher R.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":27,"n_filings":21,"first":"2023-01-26","last":"2026-05-06","span_basis":"filed_date"},"name_variants":[{"name":"Cline Christopher R.","source":"filing","n_filings":21,"first_seen":"2023-01-26","last_seen":"2026-05-06"}],"transactions":[{"id":6231849,"accession":"0001943192-26-000004","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001943192-26-000004","line_url":"/filing/0001943192-26-000004#line-3","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":310.0,"shares_display":"310","price_per_share":43.95,"price_display":"43.95","price_state":"stated","total_value":13624.5,"total_display":"13,624.50","total_whole":"13,625","shares_owned_after":118658.0,"shares_owned_after_display":"118,658","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-06","scope":"insider"},{"id":6231846,"accession":"0001943192-26-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001943192-26-000004","line_url":"/filing/0001943192-26-000004#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2181.0,"shares_display":"2,181","price_per_share":46.65,"price_display":"46.65","price_state":"stated","total_value":101743.65,"total_display":"101,743.65","total_whole":"101,744","shares_owned_after":118968.0,"shares_owned_after_display":"118,968","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-05","filed_date":"2026-05-06","scope":"insider"},{"id":5902596,"accession":"0001943192-26-000003","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001943192-26-000003","line_url":"/filing/0001943192-26-000003#line-5","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1014.0,"shares_display":"1,014","price_per_share":42.61,"price_display":"42.61","price_state":"stated","total_value":43206.54,"total_display":"43,206.54","total_whole":"43,207","shares_owned_after":116899.0,"shares_owned_after_display":"116,899","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-15","filed_date":"2026-04-15","scope":"insider"},{"id":5902594,"accession":"0001943192-26-000003","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001943192-26-000003","line_url":"/filing/0001943192-26-000003","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7248.0,"shares_display":"7,248","price_per_share":41.92773360927152,"price_display":"41.93","price_state":"stated","total_value":303892.2132,"total_display":"303,892.21","total_whole":"303,892","shares_owned_after":117913.0,"shares_owned_after_display":"117,913","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-14","filed_date":"2026-04-15","scope":"insider","n_lines":2},{"id":5902590,"accession":"0001943192-26-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001943192-26-000003","line_url":"/filing/0001943192-26-000003#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65.0,"shares_display":"65","price_per_share":28.85,"price_display":"28.85","price_state":"stated","total_value":1875.25,"total_display":"1,875.25","total_whole":"1,875","shares_owned_after":125161.0,"shares_owned_after_display":"125,161","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-13","filed_date":"2026-04-15","scope":"insider"},{"id":5759891,"accession":"0001943192-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001943192-26-000002","line_url":"/filing/0001943192-26-000002","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1745.0,"shares_display":"1,745","price_per_share":32.18790830945559,"price_display":"32.19","price_state":"stated","total_value":56167.9,"total_display":"56,167.90","total_whole":"56,168","shares_owned_after":111336.0,"shares_owned_after_display":"111,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-05","scope":"insider","n_lines":2},{"id":6048439,"accession":"0001943192-26-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001943192-26-000001","line_url":"/filing/0001943192-26-000001#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7242.0,"shares_display":"7,242","price_per_share":32.12,"price_display":"32.12","price_state":"stated","total_value":232613.04,"total_display":"232,613.04","total_whole":"232,613","shares_owned_after":112971.0,"shares_owned_after_display":"112,971","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-03","scope":"insider"},{"id":5222152,"accession":"0001943192-25-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001943192-25-000005","line_url":"/filing/0001943192-25-000005#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":35.0101,"price_display":"35.01","price_state":"stated","total_value":700202.0,"total_display":"700,202.00","total_whole":"700,202","shares_owned_after":92083.0,"shares_owned_after_display":"92,083","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-01","filed_date":"2025-12-03","scope":"insider"},{"id":4359033,"accession":"0001415889-25-023786","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-023786","line_url":"/filing/0001415889-25-023786#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":119.0,"shares_display":"119","price_per_share":19.71,"price_display":"19.71","price_state":"stated","total_value":2345.49,"total_display":"2,345.49","total_whole":"2,345","shares_owned_after":92083.0,"shares_owned_after_display":"92,083","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-04","filed_date":"2025-09-05","scope":"insider"},{"id":4359028,"accession":"0001415889-25-023786","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-023786","line_url":"/filing/0001415889-25-023786#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":454.0,"shares_display":"454","price_per_share":18.2,"price_display":"18.20","price_state":"stated","total_value":8262.8,"total_display":"8,262.80","total_whole":"8,263","shares_owned_after":92202.0,"shares_owned_after_display":"92,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-03","filed_date":"2025-09-05","scope":"insider"},{"id":4358943,"accession":"0001415889-25-023209","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-023209","line_url":"/filing/0001415889-25-023209#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":470.0,"shares_display":"470","price_per_share":17.31,"price_display":"17.31","price_state":"stated","total_value":8135.7,"total_display":"8,135.70","total_whole":"8,136","shares_owned_after":92656.0,"shares_owned_after_display":"92,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-27","filed_date":"2025-08-28","scope":"insider"},{"id":4245467,"accession":"0001415889-25-012061","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-012061","line_url":"/filing/0001415889-25-012061#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1784.0,"shares_display":"1,784","price_per_share":21.05,"price_display":"21.05","price_state":"stated","total_value":37553.2,"total_display":"37,553.20","total_whole":"37,553","shares_owned_after":93126.0,"shares_owned_after_display":"93,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-05","filed_date":"2025-05-05","scope":"insider"},{"id":4211204,"accession":"0001415889-25-010643","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-010643","line_url":"/filing/0001415889-25-010643#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48.0,"shares_display":"48","price_per_share":13.1446,"price_display":"13.14","price_state":"stated","total_value":630.9408,"total_display":"630.94","total_whole":"631","shares_owned_after":89990.0,"shares_owned_after_display":"89,990","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-11","filed_date":"2025-04-14","scope":"insider"},{"id":4174733,"accession":"0001415889-25-003062","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003062","line_url":"/filing/0001415889-25-003062#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5192.0,"shares_display":"5,192","price_per_share":20.12,"price_display":"20.12","price_state":"stated","total_value":104463.04,"total_display":"104,463.04","total_whole":"104,463","shares_owned_after":90038.0,"shares_owned_after_display":"90,038","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-04","scope":"insider"},{"id":4884987,"accession":"0001415889-25-001999","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-001999","line_url":"/filing/0001415889-25-001999#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":865.0,"shares_display":"865","price_per_share":18.9409,"price_display":"18.94","price_state":"stated","total_value":16383.8785,"total_display":"16,383.88","total_whole":"16,384","shares_owned_after":73730.0,"shares_owned_after_display":"73,730","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-22","filed_date":"2025-01-23","scope":"insider"},{"id":2156621,"accession":"0001415889-24-023091","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-023091","line_url":"/filing/0001415889-24-023091#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2490.0,"shares_display":"2,490","price_per_share":11.52,"price_display":"11.52","price_state":"stated","total_value":28684.8,"total_display":"28,684.80","total_whole":"28,685","shares_owned_after":74595.0,"shares_owned_after_display":"74,595","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-09","scope":"insider"},{"id":2485999,"accession":"0001415889-24-022992","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-022992","line_url":"/filing/0001415889-24-022992#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":514.0,"shares_display":"514","price_per_share":9.5093,"price_display":"9.51","price_state":"stated","total_value":4887.7802,"total_display":"4,887.78","total_whole":"4,888","shares_owned_after":70335.0,"shares_owned_after_display":"70,335","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-04","filed_date":"2024-09-05","scope":"insider"},{"id":2529915,"accession":"0001415889-24-010754","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-010754","line_url":"/filing/0001415889-24-010754#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54.0,"shares_display":"54","price_per_share":6.74,"price_display":"6.74","price_state":"stated","total_value":363.96,"total_display":"363.96","total_whole":"364","shares_owned_after":70849.0,"shares_owned_after_display":"70,849","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-11","filed_date":"2024-04-12","scope":"insider"},{"id":2483672,"accession":"0001415889-24-002280","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-002280","line_url":"/filing/0001415889-24-002280#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3818.0,"shares_display":"3,818","price_per_share":8.5313,"price_display":"8.53","price_state":"stated","total_value":32572.5034,"total_display":"32,572.50","total_whole":"32,573","shares_owned_after":70903.0,"shares_owned_after_display":"70,903","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-02","scope":"insider"},{"id":2324454,"accession":"0001415889-24-001798","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-001798","line_url":"/filing/0001415889-24-001798#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":853.0,"shares_display":"853","price_per_share":9.0684,"price_display":"9.07","price_state":"stated","total_value":7735.3452,"total_display":"7,735.35","total_whole":"7,735","shares_owned_after":49721.0,"shares_owned_after_display":"49,721","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":7816402,"accession":"0001209191-23-048258","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-048258","line_url":"/filing/0001209191-23-048258#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":457.0,"shares_display":"457","price_per_share":14.7102,"price_display":"14.71","price_state":"stated","total_value":6722.5614,"total_display":"6,722.56","total_whole":"6,723","shares_owned_after":50574.0,"shares_owned_after_display":"50,574","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-05","filed_date":"2023-09-05","scope":"insider"},{"id":7835226,"accession":"0001209191-23-029023","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-029023","line_url":"/filing/0001209191-23-029023#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":455.0,"shares_display":"455","price_per_share":16.59,"price_display":"16.59","price_state":"stated","total_value":7548.45,"total_display":"7,548.45","total_whole":"7,548","shares_owned_after":51031.0,"shares_owned_after_display":"51,031","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-10","filed_date":"2023-05-12","scope":"insider"},{"id":7869364,"accession":"0001209191-23-024205","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-024205","line_url":"/filing/0001209191-23-024205#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47.0,"shares_display":"47","price_per_share":21.49,"price_display":"21.49","price_state":"stated","total_value":1010.03,"total_display":"1,010.03","total_whole":"1,010","shares_owned_after":51486.0,"shares_owned_after_display":"51,486","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-11","filed_date":"2023-04-13","scope":"insider"},{"id":8722435,"accession":"0001209191-23-006422","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-006422","line_url":"/filing/0001209191-23-006422#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1588.0,"shares_display":"1,588","price_per_share":21.752,"price_display":"21.75","price_state":"stated","total_value":34542.176,"total_display":"34,542.18","total_whole":"34,542","shares_owned_after":51533.0,"shares_owned_after_display":"51,533","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-02","scope":"insider"},{"id":7994401,"accession":"0001209191-23-005032","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-005032","line_url":"/filing/0001209191-23-005032#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001943192","owner_name":"Cline Christopher R.","owner_display_name":"Cline Christopher R.","owner_url":"/insider/0001943192","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":852.0,"shares_display":"852","price_per_share":21.9044,"price_display":"21.90","price_state":"stated","total_value":18662.5488,"total_display":"18,662.55","total_whole":"18,663","shares_owned_after":32871.0,"shares_owned_after_display":"32,871","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-24","filed_date":"2023-01-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":27,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":27,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":27},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001438533","name":"Travere Therapeutics, Inc.","url":"/issuer/0001438533","role":"Officer (CHIEF FINANCIAL OFFICER)","n_filings":21,"first_seen":"2023-01-26","last_seen":"2026-05-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001943192","retrieved_at":"2026-08-27T01:13:10+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}